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Background: Serum pepsinogen (PG) I/II ratio has been widely used as “serological biopsy” for the screening of
gastric cancer (GC) and atrophic gastritis (GA). However, study concerning in situ expression of PGs is currently
insufficient, particularly for their relationship with serum PGs levels. This study was designed to investigate in situ
expression of PGI and PGII in subjects with normal mucosa (NOR), superficial gastritis (GS), GA and GC, and to
evaluate the correlations between PGs expressions in situ and in serum.
Methods: 185 subjects were enrolled for the study, including 30 NOR, 70 GS, 54 GA and 31 GC. PGI and PGII
expressions in situ and in serum were detected by immunohistochemistry and enzyme-linked immunosorbent
assay (ELISA) respectively. H. pylori immunoglobulin (Ig) G was also determined by ELISA.
Results: In situ expressions of PGI, PGII and PGI/II ratio consistently decreased in sequence of NOR/GS- > GA- > GC.
The expressions of PGI, PGII and PGI/II ratio in situ were statistically higher in youngers than in olders (P < 0.05). In
the NOR subjects, PGI staining was statistically higher in males than that in females (p = 0.02). For the correlations
between in situ and serum expressions of PGI, PGII and PGI/II ratio, a borderline correlation in the total study
sample (r = 0.131, P = 0.076) and a statistical correlation in GA cases (r = 0.307, P = 0.027) were observed for the
PGI/II ratio. The PGI expression correlated well with that of PGII in situ and in serum.
Conclusions: The in situ levels of PGI, PGII and PGI/II ratio sharply decreased in the GA and GC cases. The youngers
exhibited higher levels of PGI, PGII and PGI/II ratios than the olders. The in situ PGI/II ratio rather than PGI and PGII
alone showed certain correlation with that in serum, and the PGI expression correlated well with PGII expression.
Further studies with large-scale samples are still required to validate our findings.
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Human gastric mucosa contains two abundant and
distinguishable aspartic proteinases, namely pepsinogen
I (PGI or PGA) and pepsinogen II (PGII or PGC) [1].
The majority of PGs are present in gastric mucosa and
a small part of those may be released into blood [2].
Typically, PGs are present as zymogens in gastric mucosa
and can be converted into active proteolytic forms under
certain acidic condition in stomach lumen. The activated* Correspondence: yyuan@mail.cmu.edu.cn
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in stomach [1].
There are overwhelming epidemiological evidences
supporting that serum level of PGI and/or PGI/II ratio
correlates well with morphologic and functional changes
of gastric mucosa [3-7]. Accordingly, they have been
widely used as ‘serological biopsy’ for the screening of
gastric cancer (GC) and its precancerous lesions [3-7].
In spite of the wide use of serum PGs in clinical practice,
study concerning in situ expressions of PGs, particularly
in the stepwise progression from normal mucosa (NOR),
superficial gastritis (GS), atrophic gastritis (GA) to
carcinoma, is currently insufficient. The questions whether
the PGs expression changes in situ are synchronistic withhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sion of PGs are still not resolved based on previous studies.
These may, to some extent, puzzle the clinical work on
how to appropriately interpret the variations of serum
PGs expression in different status of gastric diseases.
The present study was conducted to investigate in situ
expressions of PGI, PGII and PGI/II ratio in the sequence
of NOR- >GS- > GA- >GC. The possible influences of
sex, age and H. pylori infection on PGs expressions in situ
were also explored. Moreover, the correlations between in
situ and serum expression of PGs and between PGI and
PGII expression in situ and in serum were evaluated.
Methods
Patients
A total of 185 subjects (male 110 and female 75)
were enrolled in this study, including NOR (n = 30),
GS (n = 70), GA (n = 54), and GC (n = 31). All the
subjects were retrospectively enrolled from a health check
program for gastric cancer screening in Zhuanghe county
of Liaoning province, China between 1998 and 2010. The
diagnosis of gastric disease was established by gastroscopic
examination and confirmed by histopathology. Histo-
pathological findings were assessed according to the
Consensus on Chronic Gastritis formulated at the
National Symposium in combination with the updated
Sydney System and the World Health Organization (WHO)
criteria [8-10]. The NOR individuals were confirmed to
have relative normal gastric mucosa without evidence of
H. pylori infection or gastrointestinal symptom. The GS
subjects have only slight or moderate superficial gastritis
without atrophic or intestinal metaplasia lesions. The GA
cases have atrophic gastritis with or without intestinal
metaplasia. Information of sex, age was retrospectively
extracted from registered documents.
This cross-sectional study was approved by the Human
Ethics Review Committee of China Medical University.
Written informed consents were obtained from the
participants.
Immunohistochemistry staining of PGI and PGII
For the retrieval of antigens, detection was performed in
5 μm-thick sections from sequentially sliced samples of
paraffin-embedded specimens. Dewaxing sections were
heated in citrate buffer (pH 6.0) using a microwave for
10 min. Overnight incubation at 4°C was carried out for
the binding of primary antibodies (PGI, anti-pepsinogen
A antibody, trade name: 2 F5, 1:600 dilution; PGII, anti-
pepsinogen C antibody, trade name: 2D5, 1:400 dilution;
both antibodies were donated by Japan Clinical Inspection
Institute) [11,12]. Afterwards, SP-two step immunostaining
was performed according to the instructions of the kit
(Kit-9801D2 from Maixin Company in Fujian, China).
For all stainings, positive controls were carried out,and staining was accepted only if controls showed
evaluable results.
Assessment of immunohistochemical staining
Immunohistochemical results were judged by IRS (im-
munoreactive score), which was determined by two
independent observers. The IRS was calculated using
two indexes of staining intensity (SI) and the percentage
of positive cells (PP). The SI in cytoplasm was graded
as: 0 = no, 1 = weak, 2 = moderate, 3 = strong staining.
The PP was categorized as: 0 = no stained cells, 1 = stained
cells < 25%, 2 = stained cells 25 ~ 50%, 3 = stained cells
51% ~ 75%; 4 = stained cells > 75%. For each sample an
IRS was calculated as SI × PP with a possible maximum
score of 12. The assessment result was defined as either
negative (0), weakly positive (1 ~ 3), positive (4 ~ 7) or
strongly positive (8 ~ 12).
In the present study, PGI staining was located in gastric
corpus glands while PGII staining was located in both
gastric corpus and antral mucosa. Therefore, PGI IRS
was only assessed in the gastric corpus mucosa, and
PGII IRS was assessed in both corpus and antral mucosa
for each participant. For PGI staining, we evaluated the
stained status of all the chief cells of gastric corpus
glands for NOR and GS subjects, the remaining chief
cells of subsistent corpus glands for GA subjects, and
cells of the cancerous lesions for GC subjects. For PGII
staining, we evaluated the staining status of all the gastric
corpus and antrum glands for NOR and GS subjects,
the remaining gastric corpus and antral glands for GA
subjects, and cells of the cancerous lesion for GC subjects.
Test for H. Pylori serology
The detailed method of examination of H. pylori serology
has been described in our previous study [13]. In brief,
about five ml of fasting venous blood was collected
from each participant. The serum sample was obtained
after centrifugation at 3000 × g for 10 minutes. Serum
Immunoglobin (Ig) G antibodies of H. pylori were detected
by enzyme-linked immunosorbent assay (ELISA) kit (Biohit
Co., Ltd., Helsinki, Finland) according to the manufacturer's
instructions. A reading of H. pylori-IgG higher than 34
EIU (enzyme immune-units) was regarded as H. pylori
seropositive.
Test for serum PGI and PGII expression
The detailed method of examination of serum pepsinogens
has been described in our previous study [14]. Approxi-
mately 5 ml fasting blood was collected from each partici-
pant. The blood was centrifuged at 3000 × g for 10 minutes
and the serum was stored immediately at −20°C until
used. Serum PGI (sPGI) and PGII (sPGII) concentrations
(microg/L) were detected by ELISA kit (Biohit Co., Ltd.,
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percent of all samples were assayed in duplicate.
Statistical analysis
All statistical analysis was performed using the SPSS
(13.0) program (SPSS, Chicago, USA). The distributions
of discrete variables were represented as frequencies and
percentages. The averages of continuous variables were
represented as median (25%, 75%). The positive rates of
PGI and PGII staining in different gastric diseases were
compared by Pearson's Chi-square test or Fisher’s exact
test. The correlation coefficient between two variables was
measured by partial correlation controlling for sex and
age. The IRS of in situ expression of PGI, PGII and PGI/II
ratio among multiple groups were compared by the
Kruskal–Wallis test; if statistical significance (P < 0.05)
was indicated, the difference between two groups was
further tested by the Mann–Whitney U-test. A two-tailed
P value less than 0.05 was considered as statistically
significant.
Result
Dynamic in situ expression of PGs in different gastric tissues
Both PGI and PGII staining were located in the cytoplasm
and cell membrane of gastric epithelial cells but in different
part of stomach. Staining for PGI was positive in corpusFigure 1 Expression of PGI in corpus glands in different gastric tissue
mucosa; (C) GA mucosa; (D) GC mucosa.mucosa but negative in all antral mucosa regardless of the
status of gastric mucosa (Figures 1 and 2). PGII staining
was present in both corpus and antral mucosa (Figures 3
and 4). None of the intestinal metaplasia cells exhibited the
PGI or PGII staining. As demonstrated in Table 1, along
the sequence of NOR/GS- >GA- >GC, the positive rates
and strongly-positive rates of both PGI and PGII expression
showed significantly decreased tendencies.
To further investigate the relative expression of PGI
to PGII in situ, the ratio of PGI IRS to PGII IRS was
calculated, namely in situ PGI/II ratio. We found that in
situ PGI/II ratios also showed a decreased tendency in the
sequence of NOR/GS- > GA- >GC, showed corresponding
average level of 1.0/1.0, 0.8 and 0 (All the IRS of PGI and
PGII staining in GC tissue were zero). In situ PGI/II ratios
in GA were statistically lower than those in GS (P = 0.005).
In situ expression of PGs in different status of sex,
age and H. pylori infection
The differences of the IRS of PGs staining between females
and males, between youngers (age < 50 years) and olders
(age ≥ 50 years), and between H. pylori seropositive and
seronegative subpopulations were evaluated in the total
study sample and in the NOR, GS and GA subgroups
(Table 2). Of the total study sample, in situ levels of PGI,
PGII and PGI/II ratio were observed to be statisticallys (immunohistochemical staining × 200). (A) NOR mucosa; (B) GS
Figure 2 Negative expression of PGI in all antral glands in different gastric tissues (immunohistochemical staining × 200).
(A) NOR mucosa; (B) GS mucosa; (C) GA mucosa; (D) GC mucosa.
Figure 3 Expression of PGII in corpus glands in different gastric tissues (immunohistochemical staining × 200). (A) NOR mucosa;
(B) GS mucosa; (C) GA mucosa; (D) GC mucosa.
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Figure 4 Expression of PGII in antral glands in different gastric tissues. (A) NOR mucosa (immunohistochemical staining × 400); (B) GS
mucosa (immunohistochemical staining × 400); (C) GA mucosa (immunohistochemical staining × 200); (D) GC mucosa
(immunohistochemical staining × 200).
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statistical differences between the youngers and the olders
in the subgroups of NOR, GS or GA. In addition, in situ
PGI expression was found to be statistically higher in males




ratevs. NOR vs. GS vs. GA vs
In situ PGI expression
NOR 30 100.00% 50.00%
GS 70 100.00% / 32.90% 0.
GA 54 83.30% 0.023c <0.001c 3.70% <0
GC 31 0.00% <0.001b <0.001b <0.001b 0.00% <0
In situ PGII expression
NOR 30 100.00% 63.30%
GS 70 100.00% / 31.40% 0.
GA 54 92.60% 0.291c 0.034c 1.90% <0
GC 31 0.00% <0.001b <0.001b <0.001b 0.00% <0
a, the ratios of PGI IRS to PGII IRS were represented as median (25%, 75%); b, the po
gastric diseases were compared by Pearson's Chi-square test; c, the positive rates of
Fisher’s exact test; d, the in situ PGI/II ratios among multiple gastric diseases were fi
significant, the Mann–Whitney test was performed to further test the different betw
bold characters.Correlations between PGs expression in situ and in serum
The expression levels of PGI, PGII and PGI/II ratio in
situ and in serum were summarized in Table 3. We
explored the correlations between in situ and serum levels
of PGI, PGII and PGI/II ratio (Table 4). A borderlineP value in situ
PGI/II ratioa
P value
. NOR vs. GS vs. GA vs. NOR vs. GS vs. GA
1.0(0.7,1.1)
021b 1.0(0.7,1.4) 0.292d
.001b <0.001b 0.8(0.4,1.1) 0.086d 0.005d




.001b <0.001b <0.001b /
sitive rates and strongly-positive rates of PGI and PGII staining in different
PGI and PGII expression in different gastric diseases were determined by
rst tested by Kruskal–Wallis test. If the result was indicated as statistically
een two groups. Analyses results with P < 0.05 were highlighted in
Table 2 In situ expression of PGs in different sex, age and H. pylori status
Total NOR GS GA
IRS scorea IRS scorea IRS scorea IRS scorea
In situ PGI staining
Sex 0.265 0.002 0.599 0.964
Female 4.0(2.0,7.0) 5.0(4.0,7.5) 6.0(4.0,9.0) 2.0(1.0,3.3)
Male 3.0(0.0,7.0) 9.0(7.0,10.5) 6.0(2.5,8.5) 2.0(1.0,3.0)
Age(years) 0.003 0.681 0.183 0.563
<50 4.0(2.0,9.0) 7.5(5.5,9.3) 7.0(3.0,10.0) 2.0(1.0,4.0)
≥50 3.0(0.0,6.0) 7.5(5.0,10.8) 5.0(3.0,7.0) 2.0(1.0,3.0)
H. pylori IgG 0.359 / 0.515 0.659
EIU < 34 3.0(1.0,6.0) 7.5(5.0,10.0) 5.0(3.0,9.3) 2.0(1.0,3.0)
EIU≥ 34 2.0(0.0,6.0) / 6.0(4.0,8.8) 2.0(1.0,3.5)
In situ PGII staining
Sex 0.073 0.363 0.245 0.643
Female 3.0(1.0,7.0) 7.0(4.5,11.0) 6.0(4.0,9.0) 3.0(1.0,5.0)
Male 5.0(2.0,7.0) 9.0(7.5,10.0) 5.0(3.0,9.0) 2.0(1.3,4.0)
Age(years) 0.003 0.198 0.260 0.173
<50 5.0(2.0,9.0) 7.5(4.0,9.0) 6.5(3.3,9.8) 3.0(2.0,5.8)
≥50 3.0(0.0,6.3) 9.5(6.0,11.0) 5.0(2.0,8.0) 2.0(1.0,4.0)
H. pylori IgG 0.942 / 0.344 0.069
EIU < 34 3.0(1.0,6.0) 8.5(5.8,10.3) 6.0(2.0,9.0) 2.0(1.0,3.0)
EIU≥ 34 3.0(0.0,6.0) / 5.5(4.0,9.8) 3.0(2.0,5.5)
In situ PGI/PGII staining
Sex 0.453 0.123 1.000 0.650
Female 0.8(0.4,1.3) 0.8(0.5,1.0) 1.0(0.7,1.5) 0.6(0.2,1.2)
Male 0.8(0.0,1.1) 1.0(0.8,1.2) 1.0(0.7,1.5) 0.8(0.4,1.0)
Age(years) 0.011 0.530 0.864 0.462
<50 1.0(0.6,1.3) 1.0(0.6,1.6) 1.0(0.7,1.4) 1.0(0.4,1.0)
≥50 0.7(0.0,1.0) 01.0(0.8,1.0) 1.0(0.7,1.5) 0.7(0.1,1.0)
H. pylori IgG 0.062 / 0.763 0.599
EIU < 34 0.9(0.3,1.4) 1.0(0.7,1.1) 1.0(0.7,1.5) 0.8(0.2,2.5)
EIU≥ 34 0.6(0.0,1.0) / 1.0(0.7,1.4) 0.7(0.4,1.0)
a, IRS of PGI, PGII and PGI/II ratio were represented as median (25%, 75%); b, in situ expression of PGI, PGII, PGI/II ratio between two groups were compared by
Mann–Whitney test. Analyses results with P < 0.05 were highlighted in bold characters.
Table 3 Expression of PGI, PGII and PGI/II ratio in situ and in serum












NOR 30 7.5(5.0,10.0) 8.5(5.8,10.3) 1.0(0.7,1.1) 68.2(47.8,146.8) 6.3(4.1,9.2) 15.3(8.9,20.2)
GS 70 6.0(3.0,9.00 6.0(3.0,9.0) 1.0(0.7,1.4) 72.5(53.5,102.3) 6.4(4.3,13.9) 9.8(7.6,14.3)
GA 54 2.0(1.0,3.0) 2.5(1.0,4.3) 0.8(0.4,1.1) 87.4(56.3,127.1) 10.7(6.6,15.6) 8.6(4.8,12.4)
GC 31 0.0(0.0,0.0) 0.0(0.0,0.0) 0.0(0.0,0.0) 86.6(64.8,139.2) 15.8(7.7,24.9) 6.1(3.7,11.7)
Note: levels of PGI, PGII and PGI/II ratio were represented as median (25%,75%).
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and In situ PGII
Serum PGI
and Serum PGII
R P value R P value R P value R P value R P value
Total −0.017 0.815 −0.138 0.063 0.131 0.076 0.737 <0.001 0.687 <0.001
NOR 0.135 0.492 0.124 0.529 0.291 0.132 0.340 0.076 0.766 <0.001
GS 0.122 0.320 0.164 0.181 −0.046 0.707 0.527 <0.001 0.705 <0.001
GA −0.131 0.356 −0.139 0.324 0.307 0.027 0.540 <0.001 0.613 <0.001
GC / / 0.091 0.639 / / / / 0.730 <0.001
Note: All the correlation coefficients were calculated by partial correlation controlling for the status of sex and age. Analyses results with P < 0.05 were highlighted
in bold characters.
Li et al. BMC Clinical Pathology 2013, 13:22 Page 7 of 10
http://www.biomedcentral.com/1472-6890/13/22correlation in the total study sample (r = 0.131, P = 0.076)
and a statistical correlation in GA cases (r = 0.307,
P = 0.027) were observed for the correlation between in
situ and serum levels of PGI/II ratio (Figure 5). However,
we found no statistical correlation between in situ and
serum expression of PGI or PGII in the total study sample
or in the subgroups of different diseases (all P > 0.05)
(Figure 6).
We further investigated the correlations between PGI
and PGII (Table 4). Notably, the changes of PGI expres-
sion correlated well with the changes of PGII expression
no matter in situ or in serum. For the correlation between
in situ PGI expression and in situ PGII expression, there
were statistically significant correlations in the total study
sample (Figure 5) and in the subgroups of GS and GA
and a borderline correlation in NOR subgroup. For the
correlation between serum PGI expression and serum
PGII expression, statistically significant correlations were
found in the total study sample (Figure 5) and in all the
subgroups of different stomach diseases.
Discussion
PGI and PGII are main progastricsins in the stomach,
which closely reflects functional and morphological
changes of gastric mucosa [15,16]. In the present study,
we found that in situ levels of PGI, PGII and PGI/II ratio
consistently decreased in sequence of NOR/GS- > GA- >
GC, especially in GA and GC. The youngers exhibited
higher levels of PGI, PGII and PGI/II ratio than the
olders. Interestingly, we found statistical correlations
between in situ and serum levels of PGI/II ratio in GA
cases and between PGI and PGII no matter in situ or in
serum. There was lack of statistical correlation between
in situ and serum expressions of PGI or PGII alone in
this study.
It is widely accepted that the carcinogenesis process of
gastric cancer progresses stepwise from normal stomach,
inflammation, precancerous conditions, and to carcinoma,
as described by Correa’s cascade [17]. In the sequence of
NOR/GS- > GA- > GC, consistently decreasing tendencies
of in situ levels of PGI, PGII and PGI/II ratio wereobserved in this study. Although both NOR and GS
subjects showed an extremely high positive rate of 100%
of in situ PGs expression, the strongly-positive rates in GS
cases significantly declined. In mild gastritis, inflammation
could stimulate the production of PGs by increasing
gastrin secretion; while in severe gastritis, the intensive
inflammation could reversely reduce the PGs production
mainly owing to injured and reduced gastric glands [18].
When it comes to GA, the positive rates of PGs expression
decreased sharply, probably because the decreasing number
of glands and prolonged inflammation response in GA
could impair normal gland function and synthesizing
capability of PGs-producing cells. Further, the synthesis
function would substantially lose in intestinal metaplasia
cells or cancerous cells.
A proportion of severe and extensive chronic GA could
evolve into severe dysplasia and even gastric carcinoma
[19]. Thus, the early diagnosis of GA is crucial for slowing
down the malignant progression process of gastric mucosa.
However, in clinical practice there is still certain difficulty
in the early recognition of atrophy and cancerous lesions
among pathologists based on haematoxylin-eosin staining
of gastric biopsy. In this study, we found that only partial
normal cells of remaining gastric glands in GA cases
exhibited weak or moderate staining of PGI and PGII, while
no PGs staining was detected in the lesions with severe
atrophy, intestinal metaplasia or carcinoma. Previously,
Waalewijn RA et al. [20] reported that PGI mRNA level in
gastric cancer tissue was relatively low. StemmerMann
GN et al. [21] showed that only 4.5% of well-differentiated
intestinal-type GC and none of diffuse-type GC was PGI-
positive staining. Our previous study also demonstrated
that the positive rates of PGII expression decreased grad-
ually in sequence of benign lesions, precancerous lesions
and gastric cancer [12]. These observations strongly
suggested that the detection of in situ PGs expression
may be important auxiliary biomarkers for the recognition
of the location of atrophy and carcinoma.
Serum PGs have been widely used as biomarkers
for GC or GA in clinical practice [3-7]. However, the
question of whether the PGs expression changes in
Figure 5 Scatter plots of correlations between in situ PGI/II ratio and serum PG/II ratio. (A) correlation between in situ PGI/II ratio and
serum PGI/II ratio in total study sample; (B) correlation between in situ PGI/II ratio and serum PGI/II ratio in NOR subgroup; (C) correlation
between in situ PGI/II ratio and serum PGI/II ratio in GS subgroup; (D) correlation between in situ PGI/II ratio and serum PGI/II ratio in
GA subgroup.
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In the present study, we explored the correlations between
in situ and serum expressions of PGs (including PGI, PGII
and PGI/II ratio) and between PGI and PGII expressions
(including in situ and in serum). However, there was lack
of correlations between in situ and serum expressions of
PGI or PGII in this study. One of the possible reasons for
negative correlations between in situ and serum expression
of PGI or PGII may be that the majority of PGs production
are restricted to gastric mucosa, and only about 1% are
released into blood, which may lead to nonsynchronousalterations between in situ and serum PGs expressions [1].
Another possible reason is that, apart from the influence
of PGs production in stomach, the inflow of PGs from
gastric epithelial cell to blood may be affected by other
potential factors, such as different damage degrees of
gastric epithelial cells, different vascular permeability,
and different metabolic mechanisms between in situ and
serum PGs [22]. Interestingly, we observed a borderline
correlation in the total study sample and a statistical
correlation in GA cases between in situ and serum levels
of PGI/II ratio. This observation indicated that in the
Figure 6 Scatter plots of correlations between pepsinogens. (A) correlation between in situ PGI (IRS scores were divided into four subgroup,
i.e. 0, 1–3, 4–7, 8–12) and serum PGI in total study sample; (B) correlation between in situ PGII (IRS scores were divided into four subgroup, i.e. 0,
1–3, 4–7, 8–12) and serum PGII in total study sample; (C) correlation between serum PGI and serum PGII in total study sample; (D) correlation
between in situ PGI (IRS score) and in situ PGII (IRS score) in total study sample.
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PGI/II ratio, rather than serum levels of PGI or PGII
alone, may be a better index that reflects the decreasing
tendencies of both PGI and PGII expression in situ. This
may partially explain why serum level of PGI/II ratio
showed a more close correlation with GC and GA but not
serum PGI or PGII alone. In addition, we found that the
PGI expression correlated well with PGII expression in
situ and in serum, which indicated that PGI and PGII
levels change simultaneously regardless of the status of
gastric mucosa. In other words, synchronous changes of
PGI and PGII expressions in situ or in serum mayspecifically reflect the damage of gastric mucosa. However,
further studies with large-scale samples are still required
to validate our findings.
We are aware that there are several limitations in this
study. First, the study sample size of each disease group
is relatively small, which limits our stratification analysis
based on different histological classifications or severity
degrees. Second, only a single method was used to detect
the status of H. pylori infection in this study population;
therefore, we only evaluated the potential influence of
different status of H. pylori serology on the in situ PGs
expression. Third, in this study we only investigated
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gastric mucosa, i.e. NOR, GS, GA and GC. A longtime
follow-up study of PGs expression in situ as well as in
serum in the same subjects whose stomach mucosa
underwent sequential changes of NOR- > GS- > GA- >
GC. Further study will be required to confirm our findings
and to better guide the further use of PGs in future
clinical practice.
Conclusions
In conclusion, the in situ levels of PGI, PGII and PGI/II
ratio sharply decreased in the GA and GC cases. The
younger people exhibited higher levels of PGI, PGII and
PGI/II ratios than the older people. The in situ PGI/II
ratio rather than PGI and PGII alone showed certain
correlation with that in serum, and the PGI expression
correlated well with PGII expression. Further studies
with large-scale samples are still required to validate our
findings.
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